11/05/2025
The Role of GLP-1 Medications in Psychiatry
GLP-1 receptor agonists, such as semaglutide, liraglutide, and tirzepatide, have emerged as valuable adjuncts in psychiatry due to their ability to promote weight loss and improve metabolic health. Weight gain is a limiting factor in using some of the most effective medications we have in psychiatry. This metabolic burden can negatively impact self-esteem, treatment adherence, and overall mental well-being, contributing to worsened mood and anxiety symptoms.
By improving glycemic control, reducing appetite, and supporting sustainable weight reduction, GLP-1 medications may mitigate these adverse effects and enhance both physical and psychological outcomes. Early evidence also suggests potential direct benefits of GLP-1 agents on neuroinflammation and cognitive function, and reducing cravings in binge eating and alcohol use disorder, further supporting their integration into comprehensive psychiatric care.
However, these medications are not without side effects. Many individuals experience gastrointestinal symptoms such as nausea or constipation, and even the manufacturers’ recommended titration schedules can be too aggressive for some patients. For this reason, we take a more conservative, individualized approach—adjusting dosing to balance effectiveness with physical comfort. We closely monitor BMI and obtain baseline and follow-up laboratory assessments, including hemoglobin A1c, lipid profile, and a comprehensive metabolic panel, to ensure the appropriateness and safety of treatment.
